Constitutive Activation of Alternative Nuclear Factor Kappa B Pathway in Canine Diffuse Large B-cell Lymphoma Contributes to Tumor Cell Survival and is a Target of New Adjuvant Therapies

Overview

Journal Leuk Lymphoma

Specialties Hematology
Oncology

Date 2016 Dec 10

PMID 27931134

Citations 5

Authors

Davis M Seelig

Daisuke Ito

Colleen L Forster

Una A Yoon

Matthew Breen

Linda J Burns

Veronika Bachanova

Kerstin Lindblad-Toh

Timothy D OBrien

Stephen C Schmechel

Anthony E Rizzardi

Jaime F Modiano

Michael A Linden

Affiliations

Soon will be listed here.

Abstract

Activation of the classical nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway is a common molecular event observed in both human and canine diffuse large B-cell lymphoma (DLBCL). Although the oncogenic potential of the alternative NFκB pathway (ANFκBP) has also been recently identified in DLBCL, its precise role in tumor pathogenesis and potential as a treatment target is understudied. We hypothesized that up-regulation of the ANFκBP plays an important role in the proliferation and survival of canine DLBCL cells, and we demonstrate that the ANFκBP is constitutively active in primary canine DLBCL samples and a cell line (CLBL1). We further demonstrate that a small interfering RNA inhibits the activation of the NFκB pathway and induces apoptosis in canine DLBCL cells. In conclusion, the ANFκBP facilitates survival of canine DLBCL cells, and thus, dogs with spontaneous DLBCL can provide a useful large animal model to study therapies targeting the ANFκBP.

Citing Articles

Genome wide exploration of the methylome in aggressive B-cell lymphoma in Golden Retrievers reveals a conserved hypermethylome.

Chu S, Avery A, Yoshimoto J, Bryan J Epigenetics. 2022; 17(13):2022-2038.

PMID: 35912844 PMC: 9665123. DOI: 10.1080/15592294.2022.2105033.

Hypermethylation-Mediated Silencing of , and Tumour Suppressor Genes in Canine DLBCL: From Multi-Omics Analyses to Mechanistic Studies.

Zorzan E, Elgendy R, Guerra G, Da Ros S, Gelain M, Bonsembiante F Int J Mol Sci. 2022; 23(7).

PMID: 35409379 PMC: 9000013. DOI: 10.3390/ijms23074021.

Improving human cancer therapy through the evaluation of pet dogs.

LeBlanc A, Mazcko C Nat Rev Cancer. 2020; 20(12):727-742.

PMID: 32934365 DOI: 10.1038/s41568-020-0297-3.

Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.

Assumpcao A, Lu Z, Marlowe K, Shaffer K, Pan X Vet Comp Oncol. 2018; 16(4):606-615.

PMID: 30101447 PMC: 6392197. DOI: 10.1111/vco.12428.

DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma.

Ferraresso S, Arico A, Sanavia T, Da Ros S, Milan M, Cascione L Sci Rep. 2017; 7(1):11591.

PMID: 28912427 PMC: 5599585. DOI: 10.1038/s41598-017-11724-w.

References

Hansen K, Khanna C . Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer. 2004; 40(6):858-80. DOI: 10.1016/j.ejca.2003.11.031. View

Davis R, Brown K, Siebenlist U, Staudt L . Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-74. PMC: 2193582. DOI: 10.1084/jem.194.12.1861. View

Gerondakis S, Siebenlist U . Roles of the NF-kappaB pathway in lymphocyte development and function. Cold Spring Harb Perspect Biol. 2010; 2(5):a000182. PMC: 2857169. DOI: 10.1101/cshperspect.a000182. View

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

Rizzardi A, Johnson A, Vogel R, Pambuccian S, Henriksen J, Skubitz A . Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol. 2012; 7:42. PMC: 3379953. DOI: 10.1186/1746-1596-7-42. View

Gaurnier-Hausser A, Patel R, Baldwin A, May M, Mason N . NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2011; 17(14):4661-71. PMC: 3273413. DOI: 10.1158/1078-0432.CCR-10-3310. View

Mudaliar M, Haggart R, Miele G, Sellar G, Tan K, Goodlad J . Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL). PLoS One. 2013; 8(9):e72591. PMC: 3762807. DOI: 10.1371/journal.pone.0072591. View

Lenz G, Davis R, Ngo V, Lam L, George T, Wright G . Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008; 319(5870):1676-9. DOI: 10.1126/science.1153629. View

Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl L, Muller W . Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med. 2008; 205(6):1317-29. PMC: 2413030. DOI: 10.1084/jem.20080238. View

10.

Oeckinghaus A, Hayden M, Ghosh S . Crosstalk in NF-κB signaling pathways. Nat Immunol. 2011; 12(8):695-708. DOI: 10.1038/ni.2065. View

11.

Ito D, Frantz A, Williams C, Thomas R, Burnett R, Avery A . CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma. 2012; 53(7):1390-8. PMC: 3727651. DOI: 10.3109/10428194.2011.654337. View

12.

Pham L, Fu L, Tamayo A, Bueso-Ramos C, Drakos E, Vega F . Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways. Blood. 2010; 117(1):200-10. PMC: 3037744. DOI: 10.1182/blood-2010-06-290437. View

13.

Odqvist L, Montes-Moreno S, Sanchez-Pacheco R, Young K, Martin-Sanchez E, Cereceda L . NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Mod Pathol. 2014; 27(10):1331-7. DOI: 10.1038/modpathol.2014.34. View

14.

Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C . Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood. 2011; 118(18):4930-4. DOI: 10.1182/blood-2011-06-359166. View

15.

Vallabhapurapu S, Karin M . Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009; 27:693-733. DOI: 10.1146/annurev.immunol.021908.132641. View

16.

Rizzardi A, Vogel R, Koopmeiners J, Forster C, Marston L, Rosener N . Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors. Cancer. 2014; 120(12):1800-9. PMC: 4047165. DOI: 10.1002/cncr.28646. View

17.

Rizzardi A, Rosener N, Koopmeiners J, Vogel R, Metzger G, Forster C . Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer. 2014; 14:244. PMC: 4101830. DOI: 10.1186/1471-2407-14-244. View

18.

Marconato L, Gelain M, Comazzi S . The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol. 2012; 31(1):1-9. DOI: 10.1002/hon.2017. View

19.

Zhao Q, Fu W, Jiang H, Du J, Zhang C, Xi H . Clinicopathological implications of nuclear factor κB signal pathway activation in diffuse large B-cell lymphoma. Hum Pathol. 2015; 46(4):524-31. DOI: 10.1016/j.humpath.2014.06.032. View

20.

Sehn L, Gascoyne R . Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2014; 125(1):22-32. DOI: 10.1182/blood-2014-05-577189. View